Physician profile
Yasoda Devi Devabhaktuni
NPI 1861442840
$7,472.57
in general payments reported to CMS, 2019-2025
55 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,377 · 2020: $345 · 2021: $233 · 2022: $399 · 2023: $505 · 2024: $1,899 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,065 · Education: $52.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,065.14 |
| Education | $52.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.95 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $975.37 | 2019-2025 | |
| Pfizer INC. | $562.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $461.90 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $356.47 | 2019-2024 | Venclexta |
| Celgene Corporation | $327.54 | 2019-2025 | Reblozyl |
| Amgen INC. | $283.22 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Lilly USA, LLC | $274.88 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $207.14 | 2019-2024 | Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $201.54 | 2019-2025 | Alunbrig, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $164.79 | 2019-2025 | Opdivo |
| Rigel Pharmaceuticals, INC. | $144.26 | 2022-2024 | Tavalisse, Rezlidhia |
| Eisai INC. | $138.27 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $133.49 | 2021-2025 | Libtayo |
| Beigene USA, INC. | $130.55 | 2021-2024 | Brukinsa |
Show all 53 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasoda Devabhaktuni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.